No misunderstanding and Apologies bow to your obvious superior knowledge, or your belief off, Actually BUb is down the path for approval and is up to clinical trials for IF, ie formulation approved etc, so much further than A2m, which has nothing. Yes toddler has less regulatory approval but BUB is smart enough to be actively working on the process for a while now, A2m -nada.
As for SAMR it has nothing to do with the states so unsure why you even raised it.
But hey according to the rusted on A2m holders they are the holly grail of all things IF but just maybe in the past they were and now they are just a slow reactive company not a market leader, I guess that is why they are still looking at updating their IF formulation where as most have moved with the market demands.
At the end of the day BUB is their selling IF even if for the initial amount, where is A2m - hoping and a wishing.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)